The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
The healthcare sector is evolving as traditional drug development meets revolutionary gene editing. Investors are now choosing between Axsome Therapeutics (NASDAQ:AXSM) and CRISPR Therapeutics (NASDAQ:CRSP) for their medical portfolios.
Axsome focuses on commercializing treatments for central nervous system disorders, while CRISPR is a leader in gene-based medicines using its flagship platform. Both companies are at critical stages of their development. They offer different risk and reward profiles for investors interested in the future of medicine and the biotech industry.
Axsome Therapeutics develops therapies for central nervous system (CNS) conditions including depression, migraine, and narcolepsy. It currently markets medicines such as AUVELITY and SUNOSI in the United States, with SUNOSI also reaching international markets. In June 2026, the company settled patent litigation for SUNOSI, which helps clear the path for its continued commercial focus among biotech stocks.
In FY 2025, revenue reached nearly $638.5 million, representing a significant increase from the previous year. This growth of approximately 65.5% was driven by the strong commercial uptake of its leading CNS products. Despite this rising revenue, the company reported a net margin of negative 28.7%, resulting in a net loss of roughly $183.2 million for the period.